Manufacturing Investment Is Accelerating. Can the Workforce Keep Pace?

As pharmaceutical and biotechnology companies expand U.S. manufacturing operations, a growing demand for specialized talent underscores the importance of industry-driven workforce development.

 

October 16, 2026 | Georgia Life Sciences

The United States is experiencing a resurgence in domestic manufacturing investment, with pharmaceutical and biotechnology companies announcing major expansions and new production facilities. But as investment accelerates, a critical challenge is emerging: ensuring that a skilled workforce is available to support this growth.

 

According to a Deloitte and The Manufacturing Institute study, approximately 3.8 million manufacturing positions could need to be filled nationwide through 2033, with as many as 1.9 million potentially remaining unfilled due to workforce and skills gaps.

 

While these projections span the broader manufacturing sector, the implications for life sciences are significant.

 

Biomanufacturing's Growing Talent Challenge

A recent PharmaVoice article examines how pharmaceutical companies are responding to growing competition for skilled workers, particularly in specialized roles such as automation engineering, quality assurance, regulatory affairs, process engineering, and manufacturing operations.

 

These positions are essential to bringing new facilities online, maintaining regulatory compliance, and ensuring safe, reliable production.

 

The challenge extends beyond competition among pharmaceutical manufacturers. Life sciences companies are increasingly competing with industries such as semiconductors, aerospace, energy, and advanced manufacturing for workers with similar technical skills.

 

Some companies are responding by investing directly in regional education and training partnerships. Eli Lilly, for example, recently committed $15 million to San Jacinto College in Texas, including $12.5 million dedicated to workforce training, alongside a major manufacturing expansion in the Houston area.

 

The message is increasingly clear: Workforce planning must begin alongside facility planning, not after construction is complete.

 

What This Means for Georgia

Georgia has an opportunity to build on its growing biomanufacturing presence, established industry base, research universities, and technical education infrastructure. However, continued success will depend on ensuring that workforce development keeps pace with industry investment.

 

As manufacturing technologies evolve, employers will need workers with expertise in automation, digital systems, quality control, and advanced production processes. Traditional education pathways alone may not be sufficient to meet these changing needs.

 

That makes stronger collaboration among employers, educational institutions, workforce organizations, and policymakers increasingly important.

 

Through its Manufacturing Council, Georgia Life Sciences is working to strengthen industry engagement and better understand employers' evolving workforce needs. These conversations help identify opportunities to align education and training with the skills companies need today and anticipate those they will require tomorrow.

 

The Georgia Life Sciences Institute also supports the long-term talent pipeline through education and workforce initiatives designed to introduce students and educators to life sciences careers and strengthen connections between education and industry.

 

Looking Ahead: Talent as a Competitive Advantage

As states compete to attract life sciences investment, workforce readiness will increasingly influence where companies choose to expand and how successfully those investments translate into long-term economic growth.

 

For Georgia, the opportunity is not simply to attract new facilities but to build the talent ecosystem necessary to sustain them.

 

That requires earlier employer engagement, flexible training models, stronger industry-education partnerships, and continued attention to emerging technologies that are changing the nature of manufacturing work.

 

The next chapter of biomanufacturing growth will be defined not only by where companies invest, but by where they can find, develop, and retain the talent needed to succeed.

 

Related Reading

Georgia Life Sciences Weighs In on PBM and 340B Policy

October 5, 2026
Georgia Life Sciences has submitted written comments to the Georgia House Study Committee on Pharmacy Benefits Managers and Consumers’ Access to Prescription Medications, encouraging greater transparency, accountability, and a focus on measurable patient benefit across the prescription drug system. The comments address both pharmacy benefit manager practices and the federal 340B Drug Pricing Program, emphasizing the importance of understanding where prescription drug savings accrue and whether those savings ultimately benefit patients. The Study Committee continues its work this fall as it develops recommendations for the Georgia General Assembly. Read Georgia Life Sciences’ full comments →

Georgia Life Sciences Joins National Coalition Calling for PAHPA Reauthorization

September 22, 2026
Georgia Life Sciences (GLS) has joined more than 80 organizations from across industry, academia, public health and the biosecurity community in calling on congressional leaders to fully reauthorize the Pandemic and All-Hazards Preparedness Act (PAHPA) before the end of 2026. Led by the Johns Hopkins Center for Health Security, the coalition urged congressional leaders to advance a comprehensive reauthorization of PAHPA, the federal framework that supports the nation’s ability to prepare for and respond to public health emergencies and other health security threats. First enacted in 2006, PAHPA established and strengthened critical components of the nation’s health security infrastructure, including the Biomedical Advanced Research and Development Authority (BARDA). The law also supports public-private partnerships involved in the research, development, manufacturing and procurement of medical countermeasures, including vaccines, therapeutics and diagnostics. PAHPA’s authorization expired in 2023 and key provisions have since continued through short-term extensions. The coalition is calling for a comprehensive reauthorization that provides greater stability and ensures the nation’s preparedness infrastructure can continue adapting to emerging biological, infectious disease and other health security threats. For the life sciences industry, these programs are particularly important. Partnerships between government and industry can help move promising technologies from research through development and manufacturing while maintaining capabilities needed to respond quickly during an emergency. The Biotechnology Innovation Organization (BIO), also a signatory to the letter, has identified several priorities for reauthorization, including continued authorization of BARDA, the Strategic National Stockpile, Project BioShield and the Pandemic Influenza Program, as well as incentives supporting the development of medical countermeasures. Georgia Life Sciences is proud to join organizations across the country in supporting a strong and sustainable national framework for health security, preparedness and biomedical innovation. Read the coalition letter and view the full list of signatories.

Georgia Life Sciences Urges Protection of Patient Access as Georgia Implements Medicaid Changes

September 14, 2026
Georgia Life Sciences has submitted comments to the Georgia Department of Community Health (DCH) regarding the Georgia Pathways to Coverage program and implementation of new federal Medicaid requirements. As Georgia prepares for these changes, Georgia Life Sciences is urging state leaders to prioritize continuity of care and minimize unnecessary administrative barriers that could delay or disrupt access to medically necessary treatment . This is particularly important for Georgians living with serious, chronic, rare, and medically complex conditions who may rely on ongoing medications, diagnostics, therapies, medical technologies, specialty care, and coordinated treatment plans. Even temporary disruptions in coverage can interrupt care and create additional challenges for patients and families. In its comments, Georgia Life Sciences encouraged DCH to protect continuity of coverage during eligibility and redetermination processes, provide patients and caregivers with clear and timely information, minimize unnecessary administrative burdens, and establish appropriate safeguards when a coverage disruption could interrupt an established course of treatment. “As Georgia implements these new federal requirements, we want to ensure that patients remain at the center of the process,” said Maria Thacker Goethe, MPH, President & CEO of Georgia Life Sciences. “Administrative changes should not become barriers between patients and the care they need. Protecting continuity of care is particularly important for Georgians managing serious and complex health conditions.” Read Georgia Life Sciences’ full comments to DCH here.
MORE POSTS